Immunome, Inc. (NASDAQ:IMNM) Receives $33.45 Average Target Price from Brokerages

Immunome, Inc. (NASDAQ:IMNM) has earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $33.4545.

A number of equities analysts recently weighed in on the stock. Truist Financial started coverage on shares of Immunome in a research note on Monday, December 1st. They set a “buy” rating and a $36.00 target price for the company. Guggenheim increased their price target on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a research report on Thursday, January 15th. HC Wainwright started coverage on Immunome in a research note on Thursday, February 12th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Lake Street Capital upped their target price on Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th.

Insider Activity at Immunome

In other Immunome news, Director Philip Wagenheim sold 36,800 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director directly owned 369,347 shares of the company’s stock, valued at approximately $7,560,533.09. The trade was a 9.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Clay B. Siegall purchased 4,729 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were acquired at an average price of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the acquisition, the chief executive officer directly owned 665,254 shares in the company, valued at approximately $14,070,122.10. This represents a 0.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 7.69% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Immunome

A number of large investors have recently bought and sold shares of IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after purchasing an additional 14,398 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Immunome by 6.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock worth $17,305,000 after purchasing an additional 117,523 shares in the last quarter. Creative Planning acquired a new stake in shares of Immunome in the 2nd quarter valued at about $167,000. Intech Investment Management LLC grew its stake in shares of Immunome by 17.8% in the 2nd quarter. Intech Investment Management LLC now owns 40,565 shares of the company’s stock valued at $377,000 after buying an additional 6,141 shares during the period. Finally, Main Management ETF Advisors LLC increased its position in Immunome by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock valued at $716,000 after buying an additional 1,248 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Price Performance

Shares of IMNM opened at $20.75 on Friday. The business has a 50-day moving average of $22.76 and a 200-day moving average of $18.64. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -8.57 and a beta of 2.12. Immunome has a 1 year low of $5.15 and a 1 year high of $27.65.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. As a group, sell-side analysts anticipate that Immunome will post -2.21 EPS for the current year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.